Plain-English translation of NCT06284486 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two medications— and —to treat acute myeloid leukemia (AML) in patients who still have detectable cancer cells after their first round of treatment. These two medications work in different ways to attack leukemia cells. The study wants to see if using them together can help eliminate the remaining cancer and prevent the disease from coming back.
After initial chemotherapy, some patients with AML still have small amounts of leukemia cells left in their bone marrow that can't be seen under a microscope. This leftover disease increases the risk that the cancer will return. This trial is testing whether this medication combination can clear out these remaining cells and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
You will take as a pill by mouth once daily for 14 days of each cycle, along with , for up to one year. After that, you will continue taking alone for another year. You'll need to take with water within 30 minutes after eating (preferably breakfast). Throughout the study, you'll have regular doctor visits to check your blood counts, bone marrow, and overall health. You can stop taking the medication early if the cancer grows worse or if you have side effects you cannot tolerate.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States